Adma Biologics (ADMA) Long-Term Deferred Tax (2016 - 2025)
Adma Biologics (ADMA) reported Long-Term Deferred Tax of $73.3 million for Q4 2025, down 13.07% on a YoY basis from $84.3 million in Q4 2024, and down 1.57% quarter-over-quarter from $74.4 million in Q3 2025.
Adma Biologics (ADMA) Long-Term Deferred Tax (2016 - 2025) Analysis & Trends
Adma Biologics has reported Long-Term Deferred Tax for 4 years, with the latest figure at $73.3 million in Q4 2025.
- For the quarter ending Q4 2025, Long-Term Deferred Tax fell 13.07% year-over-year to $73.3 million; the trailing twelve-month figure through Dec 2025 stood at $73.3 million (down 13.07% YoY), and the FY2025 full-year result was $73.3 million, down 13.07% from the prior year.
- Long-Term Deferred Tax for Q4 2025 stood at $73.3 million, down from $74.4 million in the prior quarter.
- The five-year high for Long-Term Deferred Tax was $84.3 million in Q4 2024, with the low at $73.3 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Adma Biologics | 1.98 Bn | 1.89 Bn | 88.82 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 73.26 Mn |
| Sep 30, 2025 | 74.43 Mn |
| Jun 30, 2025 | 79.24 Mn |
| Mar 31, 2025 | 80.86 Mn |
| Dec 31, 2024 | 84.28 Mn |
| Dec 31, 2018 | 624,610.00 |
| Dec 31, 2016 | 972,345.00 |